source
- Aspen Neuroscience and Bambusa Therapeutics announce plans to go public amid biotech IPO surgeAspen Neuroscience, a cell therapy company backed by Gilead, and Bambusa Therapeutics, an I&I biotech founded by former BioNTech scientists, have each filed paperwork to launch initial public offer…
- FDA review flags limited efficacy of Revolution's pancreatic cancer drug Rasonque, shares drop 6%Shares of Revolution Medicines fell about 6% after the Food and Drug Administration released review documents that suggest its pancreatic cancer therapy Rasonque may not work as well in all patient…